富祥藥業(300497.SZ):擬與凌凱醫藥在新型特種材料單體商業化生產方面展開深入合作
格隆匯10月13日丨富祥藥業(300497.SZ)公佈,2022年10月12日,公司與上海凌凱醫藥科技有限公司(簡稱“凌凱醫藥”)簽訂了《合作協議書》,協議雙方基於自身優勢,擬在新型特種材料單體(涉及:PI單體、KrF單體等)的商業化生產方面展開深入合作,推動創新技術產業化落地,該協議項下產品目前已經有部分通過終端用户的樣品測試。
凌凱醫藥·Linkchem成立於2011年,是一家致力於全合成化學技術、流體化學工程技術研發與商業化的高新技術企業,也是上海市經信委認定的專精特新企業。凌凱醫藥總部及研發中心位於上海,擁有超200人的研發團隊,旗下控股一家專業的微通道連續流領域研發公司,擅長化學工藝與流體化學工程工藝的結合應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.